This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The principle used in the analysis of effectiveness appears to have been treatment completers only. The health outcomes were clinical cure and bacteriologic cure rates. The satisfactory clinical response was the resolution of signs or symptoms of infection with sufficient clinical improvement to allow discontinuation of antibiotic therapy or a switch to oral anti-microbial therapy. Bacteriologic cure rates were determined when repeat cultures of appropriate samples were available at the end of therapy. The results were also reported in terms of subgroups of infections. The treatment groups were found to be comparable in terms of baseline demographic and clinical characteristics, except for age.
Effectiveness results
The effectiveness results were as follows:
Satisfactory clinical response was achieved in 85.9% of evaluable patients receiving A-S 1.5g, 82.5% receiving A-S 3g, and 77.5% receiving T-C 3.1g, (p=0.044).
Infecting pathogens were eradicated in 63.2% of evaluable patients (A-S 1.5g), 65.2% (A-S 3g), and 62.6% T-C 3.1g), (p=0.85).
Both agents were clinically and bacteriologically effective in patients infected with the most commonly identified pathogens.
The only significant difference among groups was a higher bacteriologic eradication rate for T-C against Pseudomonas sp, (p=0.013).
For skin and soft tissue infections, no statistically significant differences in clinical cure or bacteriologic eradication rates were apparent among the three treatments.
The three regimens also had equivalent clinical efficacy in intra-abdominal infections, but A-S had significantly superior bacteriologic efficacy to T-C in these patients (although this may be a function of the small number of patients treated with T-C).
In gynaecologic infections, no statistically significant differences in clinical or bacteriologic efficacy were noted between the two A-S doses and T-C (although the comparison was limited because only five women received T-C).
The results obtained for respiratory tract, urinary tract, and other infections generally were similar to those for skin and soft tissue, intra-abdominal, and gynaecologic infections.
No statistically significant differences in clinical or bacteriologic cure rates were found.
Clinical conclusions
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In this open, retrospective study, both 1.5g and 3.0g dosages of ampicillin-sulbactam had clinical and bacteriologic efficacy comparable with that of ticarcillin-clavulanate for the management of all except intra-abdominal infections.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported. The economic study appears to have been reduced to a cost-minimisation analysis based on the equivalent efficacy of the study regimens.
Direct costs
Costs were not discounted due to the short time frame of the cost analysis. Some quantities were reported separately from the costs and cost items were reported separately. Cost analysis covered the costs of antibiotics (level 1) on a pergram basis (acquisition cost multiplied by the total amount of drug administered) and materials required for preparation and administration (level 2) on a cost/dose basis. The perspective adopted in the cost analysis was not explicitly specified, but appears to have been that of the hospital. The sources of unit costs were each participating hospital. A cost:charge ratio of 0.6 was used to determine drug costs from charge data. The price year was not explicitly specified. Labour costs were assumed to be fixed and were therefore not included. Costs associated with adverse events and treatment failure and with hospitalisation were not collected.
Statistical analysis of costs
Cost of therapy was assessed by analyses of variance (ANOVA) and post hoc Newman-Keuls tests.
Indirect Costs
Indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
No sensitivity analysis was conducted.
Estimated benefits used in the economic analysis
Not applicable.
Cost results
The mean (SD) acquisition cost/patient (level 1) was $199.72 (281.77) in the group receiving A-S 1.5g, $335.42 (383.23) in the group receiving A-S 3.0g, and $374.35 (358.62) in the group receiving T-C; the level 1 cost of A-S 1.5g was significantly lower, (p<0.05) than that for either of the other two treatments.
The corresponding values for the preparation/administration (level 2) costs were AS 1.5g = $114.53 (133.32), A-S 3.0g = $86.79 (110.82), and T-C = $124.91 (151.88); the level 2 cost of T-C was significantly higher than that of A-S 3.0g, (p<0.05).
Authors' conclusions
In summary, in this trial ampicillin-sulbactam had efficacy comparable with that of ticarcillin-clavulanate in a variety of infections in hospitalised patients, at a potentially lower cost/course of treatment. Based on susceptibility of likely pathogens, ampicillin-sulbactam 1.5g provides adequate coverage, particularly in respiratory and urinary tract infections, and has the greatest potential for cost savings compared with either ampicillin-sulbactam 3.0g or ticarcillinclavulanate.
CRD COMMENTARY -Selection of comparators
No specific health technology appears to have been regarded as the comparator. You, as a database user, should consider which one of these or other beta-lactam/beta-lactamase-inhibitor combinations are widely used in your own setting.
Validity of estimate of measure of effectiveness
The internal validity of the effectiveness results cannot be reasonably assured due to the open-label, retrospective, nonrandomised nature of the study design, and the fact that no power calculations were performed to establish an appropriate sample size. However, the treatment groups were found to be comparable in terms of baseline demographic and clinical characteristics, except for age. The authors acknowledged that despite the similarity of the groups in terms of the above-mentioned baseline characteristics, the potential existed that A-S 1.5g was given preferentially to patients with less severe infections. The comparisons in terms of subgroups of infections may have further suffered from the shortage of patients in each subgroup; as acknowledged by the authors. The study sample appears to have been representative of the study population.
Validity of estimate of measure of benefit
The analysis of benefits appears to have been based upon therapeutic equivalence of treatment alternatives. The economic analysis therefore included only costs.
Validity of estimate of costs
The following features enhanced the validity of the cost results: some quantities were reported separately from the costs; some details of methods of cost estimation were given; the perspective adopted in the cost analysis was apparent (although not explicitly reported); a cost-to-charge ratio was used to convert charges to costs; statistical analyses were performed on some resource use and cost data. However, in terms of limitations: the price year was not reported; the cost analysis was conducted retrospectively; and the direct cost analysis omitted some important cost items. As a consequence, the cost results may not be generalisable outside the study settin
Other issues
The study results may need to be treated with some caution. The issue of generalisability to other settings or countries was not addressed, but appropriate comparisons were made with other studies. The issue of the degree to which the study sample was representative of the study population was not explicitly addressed.
Implications of the study
Since ampicillin-sulbactam has comparable activity against the pathogens responsible for most skin, gynaecologic, and intra-abdominal infections, it may be appropriate to reserve broader-spectrum agents such as ticarcillin-clavulanate for nosocomial infections, particularly those in which Pseudomonas sp are highly likely or documented. A controlled, randomised, clinical trial would be warranted to validate the study findings.
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